Novartis team scores a pioneering first in cardio R&D. But can they sell it?
Novartis is facing another blockbuster challenge of global proportions.
How do you market a heart drug with real but clearly limited health benefits? One where there’s no established ability to seriously cut down the rate of death — and headed to a field where payers are skilled at standing between patients and high-cost PCSK9 drugs?
That’s the situation for Novartis as it takes its data on canakinumab to the FDA and regulators around the world.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
